Prediction and identification of HLA-A * 0201 restricted CD8~+ CTL epitope in Mycobacterium tuberculosis Ag85C
- VernacularTitle:结核杆菌抗原Ag85C的HLA-A*0201限制性CD8~+CTL表位的预测及鉴定
- Author:
Chuanyong WU
;
Jiatao LOU
;
Tingwang JIANG
;
Cheng QIAN
;
Ye ZHOU
;
Yan CHEN
;
Bo CHEN
;
Mingli GU
;
Anmei DENG
;
Renqian ZHONG
- Publication Type:Journal Article
- Keywords:
Mycobacterium tuberculosis(Mtb);
antigens;
epitopes;
T-lymphocytes,cytotoxic
- From:
Academic Journal of Second Military Medical University
1981;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To predict and identify HLA-A * 0201 restricted CD8+ CTL epitopes in Mycobacterium tuberculosis (Mtb) antigen Ag85C, so as to provide evidence for epitope-based study for tuberculosis (TB) vaccine. Methods: The online database SYFPEITHI was applied to predict the potential HLA-A * 0201 restricted epitopes from Ag85C, an antigen of Mycobacterium tuberculosis. T2 cell line was used to assay the affinity between the predicted peptides and HLA-A * 0201 molecules. The specific CTL lines were induced from peripheral blood mononuclear cells (PBMCs) of HLA-A * 0201 positive TB patients and PPD+ healthy donors by peptides with high binding affinity to HLA-A * 0201 molecules. IFN-?production, in vitro proliferation and cytotoxicity of peptide-induced CTL were determined to screen HLA-A * 0201 restricted CD8+ CTL epitopes from those candidates. Results: Fourteen potential epitopes were identified from the SYFPEITHI database. After binding affinity assay, 3 of the 14 peptides (170-178 aa, 317-325 aa, and 144-153 aa) were found to have high binding affinity to HLA-A* 0201 molecules. However, only one peptide (144-153 aa) stimulated its specific CTL to release IFN-y, proliferate in vitro and produce specific cytotoxicity. Conclusion: We have successfully identified a HLA-A * 0201 restricted CD8+ CTL epitope of Mtb Ag85C-FLTREMPAWL( 144-153 aa) , which might be a candidate epitope for TB vaccine designing. Our findings provides a basis for developing novel and effective anti-TB vaccine.
